Signup Crypto ETF Stocks News

TJX Companies Inc Shs Cert Deposito Arg Repr 0.04545454 Sh Balance Sheet – BCBA:TJX.CI

This article presents the balance sheet for TJX Companies Inc Shs Cert Deposito Arg Repr 0.04545454 Sh (TJX.CI) on the Buenos Aires Stock Exchange. It highlights that the company's total assets for Q1 26 are ARS 49.88 trillion, a 3.68% decrease from Q4 25, while total liabilities decreased by 4.06% to ARS 35.53 trillion in the same period. The page also provides access to historical financial data, including assets, liabilities, equity, and debt.

Source: TradingView
June 13, 2026 | 00:08:39
Category: General

Cogent Communications Holdings Inc (CCOI) Stock Up 6.2% and Still Undervalued -- GF Score: 63/100

Cogent Communications Holdings Inc (CCOI) saw its stock rise by 6.2%, closing at $15.86, and is considered significantly undervalued with a GF Value™ of $64.86. Despite its undervaluation and strong profitability (8/10), the company faces substantial financial risks with a financial strength rating of 2/10, leading to a GF Score™ of 63/100. Insiders have also been selling shares, suggesting caution for potential investors.

Source: GuruFocus
June 13, 2026 | 00:09:05
Category: General

Operating cash flow per share of Central Puerto SA – BCBA:CEPU.CI

The article presents the operating cash flow per share for Central Puerto SA, traded on the Buenos Aires Stock Exchange under the ticker CEPU.CI. It shows financial data including period values and changes, with market data provided by ICE Data Services and FactSet. The page also includes various navigation and informational links related to TradingView's offerings.

Source: TradingView
June 13, 2026 | 00:10:51
Category: General

DOJ Subpoenas Put Bank Of America Regulatory And Valuation Risks In Focus

The Department of Justice has issued subpoenas to Bank of America (NYSE:BAC) regarding an investigation into potential politically motivated account closures. Concurrently, discussions are underway to reclassify Bank of America under a higher community bank threshold, which could lead to stricter regulations. These developments highlight increased legal and regulatory risks for BAC, potentially affecting its costs, product policies, and investor perceptions.

Source: Yahoo Finance UK
June 13, 2026 | 01:11:09
Category: General

U.S. Bancorp Stock: Positive Operating Leverage Growing Buybacks Shares High (NYSE:USB)

U.S. Bancorp (USB) has achieved its medium-term profitability target, leading to a significant return for investors since the author's previous coverage. The bank demonstrates disciplined cost control, converting GDP-like revenue growth into stronger pre-provision income, while maintaining stable credit quality. An improved capital ratio has enabled increased share buybacks, further boosting earnings per share, and the stock is considered to have a reasonable margin of safety.

Source: Seeking Alpha
June 13, 2026 | 01:12:37
Category: General

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio has completed its rolling submission of a New Drug Application (NDA) to the U.S. FDA for tinlarebant, intended to treat Stargardt disease type 1 (STGD1). Tinlarebant, an investigational oral therapy, targets STGD1 which is a rare, inherited retinal disease currently without approved treatments. The NDA was submitted under Breakthrough Therapy Designation, and the company awaits FDA review and potential Prescription Drug User Fee Act (PDUFA) target action date assignment.

Source: GlobeNewswire
June 13, 2026 | 01:29:53
Category: General

FDA to review Belite Bio oral therapy for retinal disease with no treatment

Belite Bio has completed its New Drug Application (NDA) submission to the U.S. FDA for tinlarebant, an oral therapy for Stargardt disease type 1 (STGD1). This marks a significant step for a disease with no current FDA-approved treatments, with Phase 3 trial results showing tinlarebant reduced retinal lesion growth. The NDA, submitted under Breakthrough Therapy Designation, now enters a 60-day FDA review period.

Source: Stock Titan
June 13, 2026 | 01:32:53
Category: General

TopBuild Wins Noteholder Consents, Amends 2032 and 2034 Senior Notes Ahead of QXO Merger

TopBuild has secured noteholder consents and executed supplemental indentures to amend its 2032 and 2034 Senior Notes. These amendments remove the Change of Control Offer related to the upcoming QXO merger, eliminate most restrictive covenants, and modify certain defeasance conditions and events of default. The changes are effective immediately but will only become operative upon satisfaction of various conditions including tender, payment, and merger completion.

Source: TradingView
June 13, 2026 | 01:34:21
Category: General

BORR Investors Have Opportunity to Join Borr Drilling Limited Fraud Investigation with the Schall Law Firm

The Schall Law Firm is investigating Borr Drilling Limited (NYSE: BORR) on behalf of investors for potential securities law violations. This investigation follows Borr's Q1 2026 financial results, which showed revenues and GAAP earnings per share below consensus estimates due to delays with the Odin drilling rig. Consequently, Borr's shares declined by over 8.7% after the announcement.

Source: Business Wire
June 13, 2026 | 01:35:03
Category: General

(DOW) Risk Channels and Responsive Allocation

Dow Inc. (DOW) is exhibiting a mid-channel oscillation pattern, with weak near and mid-term sentiment potentially challenging a positive long-term outlook. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. A significant 55.0:1 risk-reward short setup is identified, targeting a 15.3% downside against a 0.3% risk.

Source: Stock Traders Daily
June 13, 2026 | 01:37:28
Category: General

© Natavest 2025 - 2026